Trial reportFrontiers in cardiovascular medicine2026
Effects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trial.
Trial report in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation is an essential pathophysiological factor of heart failure with preserved ejection fraction (HFpEF) that supports the use of statins. The purpose of the study was to determine the effects of statin therapy with atorvastatin or rosuvastatin on functional capacity, cardiac remodeling, profibrotic and inflammatory biomarkers in patients with HFpEF. Since lipophilic and hydrophilic statins may exert different effects on HF, we also compared the effects of lipophilic atorvastatin vs. hydrophilic rosuvastatin. Methods: We enrolled 59 patients with HFpEF who had no history of statin use or had not received statins for 6 months. Participants were randomly assigned to receive atorvastatin (20-80 mg a day, Results: After 6 months of therapy, atorvastatin was associated with a greater increase in 6MWTD than rosuvastatin, but both statin groups showed comparable improvements in NYHA functional class and bicycle exercise duration. There were comparable decreases in E/e' ratio and left atrial (LA) volume index, as well as comparable improvements in diastolic (e' velocity enhancement on exercise) and chronotropic (heart rate enhancement on exercise) reserves in both statin groups. Atorvastatin was superior to rosuvastatin in modifying LA reserve (reservoir strain enhancement on exercise). A significant decrease in blood levels of all biomarkers was observed in the atorvastatin group but not in the rosuvastatin group. Rosuvastatin was associated with a reduction in hsCRP and MCP-1 only in subgroups of patients with baseline values above the median. Conclusions: In HFpEF, statin therapy appears to be associated with improved functional capacity, possibly by reducing LV filling pressure and favoring cardiac remodeling. Atorvastatin may provide some additional benefits compared with rosuvastatin. Clinical Trial Registration: https://rosrid.ru, identifier AAAA-A18-118022290061-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.